SMO ClinPlus CO.,LTD. (SHE:301257)
China · Delayed Price · Currency is CNY 33.77
+1.05 (3.21%)
At close: Oct 30, 2026
SMO ClinPlus CO.,LTD. Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Operating Revenue | 819.71 | 842.5 | 803.73 | 760.04 | 586.23 | 502.97 |
Other Revenue | 0 | 0 | - | 0 | 0 | - |
| 819.71 | 842.5 | 803.73 | 760.04 | 586.23 | 502.97 | |
Revenue Growth | 0.08% | 4.82% | 5.75% | 29.65% | 16.55% | 50.01% |
Cost of Revenue | 685 | 624.56 | 607.75 | 528.94 | 426.25 | 371.77 |
Gross Profit | 134.71 | 217.95 | 195.98 | 231.1 | 159.98 | 131.19 |
Selling, General & Admin | 58.75 | 54.25 | 52.37 | 50.28 | 49.86 | 33.74 |
Research & Development | 40.47 | 38.77 | 35.84 | 34.75 | 32.23 | 21.19 |
Other Operating Expenses | 5.96 | 5.56 | 5.29 | 5.18 | 2.99 | 2.94 |
Operating Expenses | 112.62 | 110.24 | 102.54 | 100.58 | 91.25 | 63.71 |
Operating Income | 22.09 | 107.71 | 93.44 | 130.52 | 68.73 | 67.49 |
Interest Expense | -0.05 | -0.2 | -0.44 | -0.32 | -0.18 | -0.27 |
Interest & Investment Income | 4.7 | 9.8 | 16.35 | 16.44 | 6.82 | 1.73 |
Other Non Operating Income (Expenses) | -0.42 | -4.7 | -0.77 | -0.48 | 0.19 | -0.52 |
EBT Excluding Unusual Items | 26.32 | 112.61 | 108.58 | 146.16 | 75.56 | 68.42 |
Gain (Loss) on Sale of Investments | 0.11 | 0.31 | 0.58 | 1.14 | 0.84 | -1.47 |
Gain (Loss) on Sale of Assets | 0.05 | 0.03 | -0.12 | 0.02 | 0.02 | -0.08 |
Asset Writedown | 1.71 | - | - | -0.01 | -0 | -0 |
Other Unusual Items | 14.18 | 14.94 | 12.54 | 13.72 | 4.41 | - |
Pretax Income | 42.36 | 127.88 | 121.58 | 161.03 | 80.84 | 66.88 |
Income Tax Expense | 12.71 | 18.24 | 15.15 | 26.3 | 8.43 | 9.11 |
Net Income | 29.65 | 109.64 | 106.43 | 134.73 | 72.41 | 57.77 |
Net Income to Common | 29.65 | 109.64 | 106.43 | 134.73 | 72.41 | 57.77 |
Net Income Growth | -75.61% | 3.02% | -21.00% | 86.06% | 25.35% | 63.58% |
Shares Outstanding (Basic) | 82 | 79 | 79 | 78 | 70 | 59 |
Shares Outstanding (Diluted) | 82 | 79 | 79 | 79 | 71 | 59 |
Shares Change | -6.95% | 0.78% | 0.06% | 11.32% | 20.98% | - |
EPS (Basic) | 0.36 | 1.38 | 1.35 | 1.72 | 1.04 | 0.99 |
EPS (Diluted) | 0.36 | 1.38 | 1.35 | 1.71 | 1.02 | 0.98 |
EPS Growth | -73.78% | 2.22% | -21.05% | 67.14% | 3.91% | 63.09% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -38.78 | 27.86 | -10.29 | 104.6 | 32.48 | 37.11 |
Free Cash Flow Per Share | -0.47 | 0.35 | -0.13 | 1.33 | 0.46 | 0.63 |
Dividend Per Share | 0.080 | 0.148 | 0.250 | 0.180 | 0.083 | - |
Dividend Growth | -52.38% | -40.80% | 38.89% | 116.61% | - | - |
Gross Margin | 16.43% | 25.87% | 24.38% | 30.41% | 27.29% | 26.08% |
Operating Margin | 2.70% | 12.78% | 11.63% | 17.17% | 11.72% | 13.42% |
Profit Margin | 3.62% | 13.01% | 13.24% | 17.73% | 12.35% | 11.49% |
Free Cash Flow Margin | -4.73% | 3.31% | -1.28% | 13.76% | 5.54% | 7.38% |
EBITDA | 28.79 | 114.1 | 99.42 | 135.08 | 72.29 | 70.3 |
EBITDA Margin | 3.51% | 13.54% | 12.37% | 17.77% | 12.33% | 13.98% |
D&A For EBITDA | 6.7 | 6.39 | 5.98 | 4.55 | 3.56 | 2.81 |
EBIT | 22.09 | 107.71 | 93.44 | 130.52 | 68.73 | 67.49 |
EBIT Margin | 2.70% | 12.78% | 11.63% | 17.17% | 11.72% | 13.42% |
Effective Tax Rate | 30.00% | 14.26% | 12.46% | 16.33% | 10.42% | 13.62% |
Revenue as Reported | 233.49 | 842.5 | 803.73 | 760.04 | 586.23 | 502.97 |